ORIC Pharmaceuticals, Inc. (ORIC) Revenue by Segment & Business Profile
Enozertinib (ORIC-114, EGFR inhibitor) for non-small cell lung cancer was 100.0% of ORIC Pharmaceuticals, Inc.'s revenue, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ORICORIC Pharmaceuticals, Inc.Follow ORIC — free
—
Price chart with a free account
- Market cap
- 1.4B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
What the company does
ORIC Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector.
Roles we read
from the filings, not the sector label- Clinical-stage developer
ORIC Pharmaceuticals, Inc. — questions
- What does ORIC Pharmaceuticals, Inc. do?
- ORIC Pharmaceuticals, Inc. is a biotechnology company in the healthcare sector.
- How does ORIC Pharmaceuticals, Inc. make money?
- By the lines it reports in its SEC filings: Enozertinib (ORIC-114, EGFR inhibitor) for non-small cell lung cancer 100.0% of revenue.
Every figure on this page comes from ORIC Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.